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Abstract
Acute  lymphoblastic  leukemia  (ALL)  is  the
most frequent neoplasm in children, while being
relatively rare in adults. The outcome of children
with ALL is far superior than that observed in
adults, whose survival rates generally do not ex-
ceed 40%. A retrospective analysis recently car-
ried out on a large series of cases enrolled in the
AIEOP and GIMEMA protocols for the treatment of
pediatric and adult ALL has documented specific
differences among the various age cohorts exam-
ined, particularly in terms of incidence of molec-
ular  rearrangements,  with  the BCR/ABL  re-
arrangement being detected in more than half of
patients in the 6th decade of life. These findings
highlight the importance of a precise diagnostic
screening at all ages, since elderly patients might
benefit more from targeted approaches, that are
associated with less toxic effects. Furthermore,
extended  biologic  approaches  aimed  at  identi-
fying  novel  therapeutic  targets  should  be  re-
garded as a main goal to refine our therapeutic
armamentarium.
Finally, the introduction of pediatric-like proto-
cols  is  progressively  changing  the  outcome  of
young  adult  patients,  although  an  important
caveat is represented by the comorbidities and
toxic  effects  associated  with  more  aggressive
chemotherapy; therefore, patients’ fitness should
always be carefully considered.
Acute  lymphoblastic  leukemia  (ALL)  is  the
most frequent neoplasm in children, whereas it is
more rare in adults. Over the last decades, there
has  been  a  considerable  improvement  in  the
management and outcome of childhood ALL, with
CR rates and long-term survivals reaching 95%
and 80%, respectively. At variance, in adults the
clinical scenario is significantly different, mostly
in terms of survival rates, which generally do not
exceed 40%.
Several features can at least in part explain
this marked difference in prognosis; these in-
clude – among others – more intensive regimens,
less side effects and a higher compliance to ag-
gressive  chemotherapy  schedules  in  children,
while in adults the toxic effects often represent a
considerable limit to the administration of ade-
quate drug doses and to the correct timing of
chemotherapy. As a proof of principle of these
concepts, it has been widely reported that adoles-
cents and young adults (also called AYA) treated
with pediatric-like regimens, have a superior out-
come.
Moreover, a number of biologic features are re-
sponsible for the different clinical scenario, such
as an increased incidence in older patients of the
BCR/ABL  and  ALL1/AF4 transcripts,  known  to
have a negative impact on prognosis, and a de-
creased incidence of the ETV6/RUNX1rearrange-
ment, associated with a favorable outcome; fur-
thermore, it has been reported that older patients
(>60 years) tend to have a decreased male/female
ratio and a decreased incidence of organomegaly.
Taking advantage of the availability of two large
databases  of  the  Italian  multicenter  protocols
AIEOP (Associazione Italiana Ematologia ed On-
cologia Pediatrica) and GIMEMA (Gruppo Italiano
Malattie EMatologiche dell’Adulto) for the treat-
ment of pediatric and adult ALL, respectively, we
have recently evaluated retrospectively the clinico-
biologic features of more than 5000 patients, sub-
divided in different age groups (1-5, 5-10, 10-14,
14-18, 18-25, 25-20, 30-40, 40-50, 50-60 years).
The analysis of this large cohort of patients has
allowed to highlight, as expected, a peak in the in-
cidence of ALL in the age groups 1-5 and 5-10,
with a progressive decrease from 10 to 30 years
and an increase from 30 years onwards. Interest-
ingly, gender distribution highlighted an overall
lower  incidence  of  females:  this  phenomenon
was remarkable between 14-50 years and disap-
peared  in  the  50-60  age-cohort.  Furthermore,
there  was  a  significant  association  between
gender and immunophenotype, T-ALL being more
frequent in males up to the 4th decade. Molecular
screening showed that the ETV6/RUNX1+ virtu-
ally disappeared in adult patients; furthermore, it
also highlighted a progressive increase of two
molecular rearrangements known to be associ-
ated with a very poor outcome, namely ALL1/AF4
and BCR/ABL, the latter being detected in more
than 50% of individuals in the 6th decade of life.
These findings provide a further biologic ra-
tionale  for  the  progressive  implementation  of
novel targeted therapeutic approaches directed
against specific targets. Two illuminating exam-
ples in this sense are given by two consecutive
Italian  protocols  for  the  treatment  of  adult
BCR/ABL+ ALL patients. The first protocol, the
GIMEMA LAL 0201B study, enrolled only elderly
patients (>60 years) and was based on the ad-
ministration of corticosteroids for the first week
of treatment followed thereafter by imatinib, the
first tyrosine kinase inhibitor specifically directed
against the ABL protein, at the dose of 800 mg
daily,  associated  to  steroids  without  further
chemotherapy  as  frontline  treatment.  The  me-
dian age was 69 years and, remarkably, all pa-
tients obtained a complete hematologic remis-
sion, with a consistent reduction of the BCR-ABL
transcripts. This schedule allowed a reduced hos-
pitalization, was not coupled to major toxicities
and treatment was well tolerated.
In the second study, the GIMEMA LAL1205 pro-
tocol, designed for adult individuals (>18 years)
with a BCR/ABL+ ALL, dasatinib – one of the most
potent  second-generation  tyrosine  kinase  in-
hibitors – was administered 70 mg twice daily for
a total of 84 days, and was preceded by a week of
corticosteroids: also with this schedule, all pa-
tients obtained a complete hematologic remis-
sion and had a good quality of life.
Overall, these two studies have shown that also
elderly patients with BCR/ABL+ ALL, previously
considered eligible only for palliative treatment
strategies, may be spared chemotherapy and suc-
cessfully managed with a targeted therapeutic ap-
proach. Furthermore, they underline the impor-
tance of performing a precise diagnostic work-up
at all ages, with the final goal of providing all pa-
tients with the best therapeutic option.
Another example is represented by the specific
overexpression of the Flt3 kinase in patients car-
rying the ALL1/AF4 rearrangement and in a sub-
group of children and adults without known mo-
lecular aberrations. Although this finding has so
far not translated into the clinical practice, it is in-
triguing to speculate that regimes including Flt3
inhibitors might be of benefit for ALL patients
who have high expression levels of this kinase
and who are known to have an unfavorable prog-
nostic likelihood.
In  conclusion,  stratification  of  patients  ac-
cording to age groups is associated with important
clinical and biologic features that might be in part
responsible of the marked differences in the out-
come witnessed in children and adults with ALL.
The introduction of pediatric-like regimes for
the management of young adults is progressively
changing the outcome for this subgroup of pa-
tients, although some important questions still
remain open. In particular, a clear cut-off for the
definition of young adults has so far not been es-
tablished and the burden of toxicities associated
with these more aggressive therapeutic regimens
in terms of compliance to treatment, quality of life
and overall survival is at present not conclusively
defined for the different age ranges.
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